Search Results - "Castel Ajgal, Zahra"

HDAC Inhibition to Prime Immune Checkpoint Inhibitors by Borcoman, Edith, Kamal, Maud, Marret, Grégoire, Dupain, Celia, Castel-Ajgal, Zahra, Le Tourneau, Christophe

“…Immunotherapy has made a breakthrough in medical oncology with the approval of several immune checkpoint inhibitors in clinical routine, improving overall…”
Get full text

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial by Rodrigues, Manuel, Vanoni, Giulia, Loap, Pierre, Dubot, Coraline, Timperi, Eleonora, Minsat, Mathieu, Bazire, Louis, Durdux, Catherine, Fourchotte, Virginie, Laas, Enora, Pouget, Nicolas, Castel-Ajgal, Zahra, Marret, Gregoire, Lesage, Laetitia, Meseure, Didier, Vincent-Salomon, Anne, Lecompte, Lolita, Servant, Nicolas, Vacher, Sophie, Bieche, Ivan, Malhaire, Caroline, Huchet, Virginie, Champion, Laurence, Kamal, Maud, Amigorena, Sebastian, Lantz, Olivier, Chevrier, Marion, Romano, Emanuela

“…Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and…”
Get full text

Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer by Loriot, Yohann, Kamal, Maud, Syx, Laurene, Nicolle, Remy, Dupain, Celia, Menssouri, Naoual, Duquesne, Igor, Lavaud, Pernelle, Nicotra, Claudio, Ngocamus, Maud, Lacroix, Ludovic, Tselikas, Lambros, Crehange, Gilles, Friboulet, Luc, Castel-Ajgal, Zahra, Neuzillet, Yann, Borcoman, Edith, Beuzeboc, Philippe, Marret, Grégoire, Gutman, Tom, Wong, Jennifer, Radvanyi, Francois, Dureau, Sylvain, Scoazec, Jean-Yves, Servant, Nicolas, Allory, Yves, Besse, Benjamin, Andre, Fabrice, Le tourneau, Christophe, Massard, Christophe, Bieche, Ivan

Get full text

The genomic and transcriptomic landscape of metastastic urothelial cancer by Loriot, Yohann, Kamal, Maud, Syx, Laurene, Nicolle, Remy, Dupain, Celia, Menssouri, Naoual, Duquesne, Igor, Lavaud, Pernelle, Nicotra, Claudio, Ngocamus, Maud, Lacroix, Ludovic, Tselikas, Lambros, Crehange, Gilles, Friboulet, Luc, Castel-Ajgal, Zahra, Neuzillet, Yann, Borcoman, Edith, Beuzeboc, Philippe, Marret, Grégoire, Gutman, Tom, Wong, Jennifer, Radvanyi, Francois, Dureau, Sylvain, Scoazec, Jean-Yves, Servant, Nicolas, Allory, Yves, Besse, Benjamin, Andre, Fabrice, Le tourneau, Christophe, Massard, Christophe, Bieche, Ivan

“…Metastatic urothelial carcinoma (mUC) is a lethal cancer, with limited therapeutic options. Large-scale studies in early settings provided critical insights…”
Get full text

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine by Dupain, Célia, Gutman, Tom, Girard, Elodie, Kamoun, Choumouss, Marret, Grégoire, Castel-Ajgal, Zahra, Sablin, Marie-Paule, Neuzillet, Cindy, Borcoman, Edith, Hescot, Ségolène, Callens, Céline, Trabelsi-Grati, Olfa, Melaabi, Samia, Vibert, Roseline, Antonio, Samantha, Franck, Coralie, Galut, Michèle, Guillou, Isabelle, Halladjian, Maral, Allory, Yves, Cyrta, Joanna, Romejon, Julien, Frouin, Eleonore, Stoppa-Lyonnet, Dominique, Wong, Jennifer, Le Tourneau, Christophe, Bièche, Ivan, Servant, Nicolas, Kamal, Maud, Masliah-Planchon, Julien

“…High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received…”
Get full text

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial by Hilmi, Marc, Kamal, Maud, Vacher, Sophie, Dupain, Célia, Ibadioune, Sabrina, Halladjian, Maral, Sablin, Marie Paule, Marret, Grégoire, Ajgal, Zahra Castel, Nijnikoff, Michèle, Salomon, Anne, El Beaino, Zakhia, Servant, Nicolas, Dureau, Sylvain, Sokol, Harry, Nicolle, Remy, Le Tourneau, Christophe, Bieche, Ivan, Neuzillet, Cindy

“…Data on the role of the microbiota in cancer have accumulated in recent years, with particular interest in intratumoral bacteria. Previous results have shown…”
Get full text

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp by Rodrigues, Manuel, Saint-Ghislain, Mathilde, Ramtohul, Toulsie, de Koning, Leanne, Bouchez, Clémentine, Lafite, Elsa, Castel Ajgal, Zahra, Marret, Gregoire, Sanchez, Raphaël, Mariani, Pascale, Nespoulous, Sandra, Gillon, Véronique, Servois, Vincent, Piperno-Neumann, Sophie

“…TPS9613 Background: Up to 50% of pts with uveal melanoma (UM) develop metastases, mainly hepatic, with poor overall survival and limited treatment options as…”
Get full text

Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers by Borcoman, Edith, Lalanne, Ana, Delord, Jean-Pierre, Cassier, Philippe A., Rolland, Frédéric, Salas, Sébastien, Limacher, Jean-Marc, Capitain, Olivier, Lantz, Olivier, Ekwegbara, Christina, Jeannot, Emmanuelle, Cyrta, Joanna, Tran-Perennou, Carine, Castel-Ajgal, Zahra, Marret, Grégoire, Piaggio, Eliane, Brandely, Maud, Tavernaro, Annette, Makhloufi, Hakim, Bendjama, Kaidre, Le Tourneau, Christophe

“…To evaluate tipapkinogene sovacivec (TG4001), a viral immunotherapeutic vaccine expressing human papillomavirus (HPV)16 E6/E7 non-oncogenic proteins and IL-2,…”
Get full text

Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab by Castel-Ajgal, Zahra, Goulvestre, Claire, Zaibet, Sonia, Arrondeau, Jennifer, Bretagne, Marie, Peyromaure, Michael, Batteux, Fréderic, Alexandre, Jerome, Goldwasser, Francois, Huillard, Olivier

“…•No predictive biomarker of immune related adverse events exists.•We assessed the predictive value of ANA for toxicity of pembrolizumab.•Presence of ANA >160…”
Get full text

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study by Vauchier, Charles, Auclin, Edouard, Barthélémy, Philippe, Carril-Ajuria, Lucia, Ryckewaert, Thomas, Borchiellini, Delphine, Castel-Ajgal, Zahra, Bennamoun, Mostefa, Campedel, Luca, Thiery-Vuillemin, Antoine, Coquan, Elodie, Crouzet, Laurence, Berdah, Jean-François, Chevreau, Christine, Ratta, Raffaele, Fléchon, Aude, Lefort, Felix, Albiges, Laurence, Gross-Goupil, Marine, Vano, Yann-Alexandre, Thibault, Constance, Oudard, Stéphane

“…Introduction. Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive…”
Get full text

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab by Noel, Johanna, Jouinot, Anne, Alexandre, Jérôme, Ulmann, Guillaume, Bretagne, Marie, Castel-Ajgal, Zahra, De Percin, Sixtine, Vaquin-Villeminey, Clémentine, Revel, Marie-Pierre, Peyromaure, Michael, Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Gataa, Ithar, Durand, Jean-Philippe, Goldwasser, François, Huillard, Olivier

“…Background: Nivolumab improved patients’ survival in metastatic renal cell carcinoma (mRCC). We aimed to evaluate resting energy expenditure (REE) (i.e.,…”
Get full text